Minimally Important Differences for Interpreting EORTC QLQ-C30 Scores in Patients With Advanced Breast Cancer.
Jammbe Z MusoroCorneel CoensFrederic FiteniPogoda KatarzynaFatima CardosoNicola S RussellMadeleine T KingKim CocksMirjam Ag SprangersMogens GroenvoldGalina VelikovaHans-Henning FlechtnerAndrew Bottomleynull nullPublished in: JNCI cancer spectrum (2019)
Our findings aid interpretation of changes in EORTC QLQ-C30 scores over time, both within and between groups, and for performing more accurate sample size calculations for clinical trials in advanced breast cancer.